- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 31.10. | Ventus gears up for phase 2 study of potential daily oral lupus drug after passing early-stage test | ||
| 31.10. | Compass veers off course, delaying phase 3 psychedelic data and laying off 30% of staff | ||
| 31.10. | Takeda stops phase 2 sleep apnea trial over slow enrollment | ||
| 31.10. | Amgen ghosts lung disease program after missing all 14 endpoints | ||
| 30.10. | CRO Lindus Health launches 'all-in-one' service for women's health clinical trials | ||
| 30.10. | Medable launches its clinical trial software solutions into the Google Cloud Marketplace | ||
| 30.10. | TCT 2024: Valve under-expansion plagues Boston Scientific's head-to-head TAVR trial | ||
| 30.10. | Roche sees rapid amyloid clearing in Alzheimer's study, adjusts protocol after patient death | ||
| 30.10. | Biogen buys in to molecular glues with Neomorph deal worth up to $1.45B | ||
| 30.10. | Eli Lilly rolls the dice, axing psoriasis prospect and pivoting to follow-up 1 year after $2.4B buyout | ||
| 30.10. | TCT 2024: J&J's Abiomed clears pivotal study for shrinkable heart pump | ||
| 30.10. | GSK axes vaccine from $2.1B deal, switching to preclinical successor over 'increased competition' | ||
| 30.10. | Spero speared by antibiotic flop, triggering 39% workforce cut | ||
| 29.10. | Medidata and Cogstate combine data tools and cognitive assessments to improve CNS trials | ||
| 29.10. | In conversation with Boston Scientific's global medical chief, Ken Stein, taking the pulse of pulsed field ablation | ||
| 29.10. | TCT 2024: Abbott's coronary atherectomy study fails to outperform conventional balloon angioplasty | ||
| 29.10. | Korea's GemVax misses mark with peptide drug in phase 2a study in progressive supranuclear palsy | ||
| 29.10. | Pfizer, amid Abyrsvo launch, lets its RSV pipeline dry up in crowded space | ||
| 29.10. | Crescent Biopharma inks GlycoMimetics merger, securing Nasdaq listing and $200M for hot cancer program | ||
| 29.10. | Innovent, awaiting Chinese regulators' verdict, posts another psoriasis win for IL-23 drug | ||
| 29.10. | With BIOSECURE Act looming, WuXi AppTec sustains another revenue decline while still attracting new business | ||
| 29.10. | Coya touts partnership potential as IL-2 prospect comes through small Alzheimer's study | ||
| 29.10. | GSK aims to extend lupus dominance via $300M upfront deal for clinical-stage T-cell engager | ||
| 29.10. | Neurocrine, Idorsia part ways 2 years after collab's double phase 2 fails | ||
| 29.10. | Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
